GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (STU:BO1) » Definitions » 3-Year Revenue Growth Rate

BioCryst Pharmaceuticals (STU:BO1) 3-Year Revenue Growth Rate : 35.50% (As of Dec. 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals 3-Year Revenue Growth Rate?

BioCryst Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2024 was €0.61.

During the past 12 months, BioCryst Pharmaceuticals's average Revenue per Share Growth Rate was 26.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 35.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 62.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of BioCryst Pharmaceuticals was 528.00% per year. The lowest was -70.70% per year. And the median was 5.05% per year.


Competitive Comparison of BioCryst Pharmaceuticals's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's 3-Year Revenue Growth Rate falls into.



BioCryst Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


BioCryst Pharmaceuticals  (STU:BO1) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


BioCryst Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals Headlines

No Headlines